Clinical Trial

Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)

Study acronym: DOTS-AD
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated August 29, 2024 (before its estimated July 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by double-blind, randomized adjunctive treatment with clonazepam or pregabalin for persistent symptoms.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-01-27; most recent amendment 2024-08-28.
Trial Details
NCT Number NCT04245748
Lead Sponsor University of Cincinnati
Conditions Anxious Depression, Depression
Enrollment 84 participants
Start Date 2020-03-01
Primary Completion 2025-07-30 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-29